Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 2/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248014 | 0.91 | MAOB (0.38) | RXFP1ADAMTS5ALDH1A1CISD1MAOB | |
| SCHEMBL14003394 | 0.87 | GSK3B (0.32) | RXFP1MEN1KMT2APOLBBLM | |
| SCHEMBL4248380 | 0.85 | CISD1 (0.37) | ALDH1A1CISD1MAOBMEN1KMT2A | |
| SCHEMBL2798454 | 0.84 | CTSD (0.40) | BACE1CISD1SLC6A3 | |
| SCHEMBL4247312 | 0.78 | HSP90AA1 (0.34) | ALDH1A1CISD1SLC6A2CHRNA4SLC6A3 | |
| SCHEMBL4252684 | 0.77 | LDHA (0.37) | ALDH1A1CISD1MEN1KMT2A | |
| SCHEMBL4252191 | 0.76 | CISD1 (0.33) | CISD1 | |
| SCHEMBL8278809 | 0.76 | MAOB (0.38) | ALDH1A1ATMCISD1MAOBMAOA | |
| SCHEMBL8275987 | 0.76 | MAPT (0.38) | ALDH1A1CISD1MAOBMEN1KMT2A | |
| SCHEMBL4010300 | 0.74 | CDK4 (0.35) | ALDH1A1ATMCISD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044072-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| EP-2035423-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2035424-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA. | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007145568-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145568-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145569-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145569-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145571-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| WO-2007145571-A9 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080051420-A1 | New Compounds 317 | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051420-A1 | New Compounds 317 | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051420-A1 | New Compounds 317 | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007145571-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145571-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145568-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145568-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145569-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214577-A1 | New Compounds 320 | PSEN1, PSEN2, MAPT | RXFP1 3907/4885BACE1 5/4885ADAMTS5 3126/4885 |
| US-20080058349-A1 | New Compounds 318 | PSEN2, PSEN1, MAPT | RXFP1 4044/4885BACE1 5/4885ADAMTS5 3443/4885 |
| US-20080051420-A1 | New Compounds 317 | PSEN2, PSEN1, MAPT | RXFP1 4102/4885BACE1 6/4885ADAMTS5 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.